New torsemide formulation aims to ease bladder symptoms in heart failure

NCT ID NCT06206512

Completed Symptom relief Sponsor: Sarfez Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an extended-release version of the diuretic torsemide works better than the standard immediate-release form for reducing overactive bladder symptoms in people with chronic heart failure. Twenty-four participants took each version for four weeks, tracking their urinary symptoms and quality of life. The goal was to see if the extended-release form causes fewer bladder problems while still managing fluid buildup.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: torsemide (extended release and immediate release)
What this could lead to: If it works, this could point toward a better-tolerated diuretic that reduces bothersome bladder symptoms in heart failure patients.
What could go wrong: This is a small, early Phase 2 trial with only 24 participants, so results may not apply widely. Torsemide can cause kidney injury, electrolyte loss, and hearing issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC CONGESTIVE HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE INCONTINENCE OVERACTIVE BLADDER

Contacts and locations

Locations

Cardiometabolic Research Unit

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.